Abstract:Background Prevalence of cardiovascular disease risk factors and rates of atherosclerotic cardiovascular disease outcomes vary across racial/ethnic groups. This analysis examined the effects of evolocumab on LDL‐C (low‐density lipoprotein cholesterol) levels and LDL‐C goals achievement by race/ethnicity. Methods and Results Data from 15 phase 2 and 3 studies of treatment with evolocumab versus placebo or ezetimibe were pooled (n=7669). Results were analyzed by participant clinical characteristics and by self‐identified race/ethnicity. Key outcomes included percent change from baseline in LDL‐C, achievement of LDL‐C <70 mg/dL, and LDL‐C reduction of ≥50% at 12 weeks and at 1 to 5 years. Across 12‐week studies, mean percent change in LDL‐C from baseline in evolocumab‐treated participants was −52% to −59% for White and −46% to −67% for non‐White participants, across clinical characteristics groups. LDL‐C <70 mg/dL was achieved in 43% to 84% and 62% to 94% and LDL‐C reduction of ≥50% in 63% to 78% and 58% to 86%, respectively. In 1‐ to 5‐year studies, mean percent change in LDL‐C was −46% to −52% for White and −49% to −55% for non‐White participants. LDL‐C <70 mg/dL was achieved in 53% to 84% and 66% to 77%, and LDL‐C reduction of ≥50% in 53% to 67% and 58% to 68%, respectively. The treatment effect on mean percent change in LDL‐C differed only in participants with type 2 diabetes mellitus, with a larger reduction in Asian participants. The qualitative interaction P values were nonsignificant, indicating consistent directionality of effect. Conclusions Similar reduction in LDL‐C levels with evolocumab was observed across racial/ethnic groups in 12‐week and 1‐ to 5‐year studies. Among those with diabetes mellitus, Asian participants had greater LDL‐C reduction. Nonstandard Abbreviations and Acronyms PCSK9 proprotein convertase subtilisin/kexin type 9 Q2W every 2 weeks (dosing regimen) QM once monthly (dosing regimen) Clinical Perspective What Is New? Lipid‐lowering therapy with evolocumab, a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor, substantially reduces LDL‐C (low‐density lipoprotein cholesterol) in patients with a broad range of clinical characteristics. In this pooled analysis, evolocumab therapy was associated with similar reductions in LDL‐C across racial/ethnic groups in both 12‐week and 1‐ to 5‐year studies (eg, in 12‐week studies, mean percent change in LDL‐C from baseline in evolocumab‐treated participants was −52% to −59% for White and −46% to −67% for non‐White participants across clinical characteristic groups, and LDL‐C <70 mg/dL was achieved in 43–84% and 62–94%, respectively). Among those with diabetes mellitus, Asian participants had greater reduction in LDL‐C. What Are the Clinical Implications? These findings provide further evidence for the use of evolocumab therapy to lower LDL‐C in individuals of diverse racial/ethnic backgrounds, including those with diabetes mellitus. Prevalence of major cardiovascular disease (CVD) risk factors and rates of CVD outcomes vary markedly by race and ethnicity. 1 , 2 Non‐Hispanic Black participants experience higher age‐adjusted rates of stroke and mortality because of CVD, and higher rates of major CVD comorbid conditions compared with non‐Hispanic White participants. 1 , 3 Rates of elevated total cholesterol and LDL‐C (low‐density lipoprotein cholesterol) levels vary by race/ethnicity (ie, rates are higher in Hispanic men compared with non‐Hispanic White men), while prevalence of elevated LDL‐C level in non‐Hispanic Black men is similar to that among non‐Hispanic White men. 1 Non‐Hispanic White women have the highest rates of elevated total cholesterol and LDL‐C levels. 1 The burden of low HDL‐C (high‐density lipoprotein cholesterol)/high triglyceride dyslipidemia appears greater in -Abstract Truncated-

Differences in Clinical Outcomes Between Non-Obese Caucasians and African American Populations with Hyperlipidemia

Differences in Clinical Outcomes between Non-Obese African American and Asian Populations Who have Hyperlipidemia

Association Between Socio-demographic and Clinical Factors and Health Outcomes among COVID-19 Patients in a Community Hospital in Alabama

FRI660 Serum Lipids And Inflammatory Markers Reveal Race-associated Differences Between Diabetics And Non-diabetics

Racial Disparities In Outpatient Medical Management Of Patients With Heart Failure With Reduced Ejection Fraction

Race/Ethnic Differences in Atherosclerotic Cardiovascular Disease Risk Factors Among Patients With Hypertension: Analysis From 143 Primary Care Clinics

Long-Term Mortality in Patients With Severe Hypercholesterolemia Phenotype From a Racial and Ethnically Diverse US Cohort

Obesity and intermediate clinical outcomes in diabetes: evidence of a differential relationship across ethnic groups

Disparities among ethnic groups in mortality and outcomes among adults with MASLD: A multicenter study

Race and Sex Differences in Diabetic Complications in a Large Health Care System

Racial and Ethnic Disparities in Management and Outcomes of Cardiac Arrest Complicating Acute Myocardial Infarction

Abstract 16059: Real-World Exploration of Low Density Lipoprotein Cholesterol Management in Patients With Atherosclerotic Cardiovascular Disease

The impact of ethnicity on clinical outcomes in patients with heart failure and atrial fibrillation

Racial and ethnic disparities in cardiovascular disease - analysis across major US national databases

Comparison of Long-Term Outcomes Between Older Asian and White Patients with Non–st-Segment Elevation Myocardial Infarction: Findings from CRUSADE-CMS Database

Racial/ethnic differences in treatment recommendations: lifestyle changes and medication prescriptions for high cholesterol

A Retrospective Analysis of Hyperlipidemia and COVID-19 Outcomes Investigated in a Rural Midwestern Population

Abstract 9851: Mortality and Post-Discharge Acute Care Utilization for Cardiovascular Conditions at US Safety-Net and Non-Safety-Net Hospitals

Effects of Evolocumab on Low-Density Lipoprotein Cholesterol, Non-High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta-Analysis of Individual Participant Data From Double-Blind and Open-Label Extension Studies.

Ethnic disparity in the care and management of non-ST-segment elevation myocardial infarction and its impact on short-term and long-term survival: a long-term study of a national registry

Disparate outcomes in Hispanic patients with metabolic dysfunction-associated steatotic liver disease/steatohepatitis and type 2 diabetes: Large cohort study